16/10/2026
Delesalle et al. report the successful use of dupilumab in a patient with refractory linear IgA dermatosis (LAD) who could not continue standard therapies.
Rapid clearance was achieved within 15 days, with no recurrence after 6 months, supporting dupilumab as a potential treatment option in selected cases.
Full details 👉 https://onlinelibrary.wiley.com/doi/10.1002/jvc2.70285